Status of Personal Importation of Prescription Medicine Bills in Congress
S.122 -
Safe and Affordable Drugs from Canada Act of 2015114th Congress (2015-2016)
BILL
Sponsor:
|
Sen.
McCain, John [R-AZ] (Introduced 01/08/2015)
|
Committees:
|
Senate -
Health, Education, Labor, and Pensions
|
Latest
Action:
|
01/08/2015
Read twice and referred to the Committee on Health, Education, Labor, and
Pensions. (All
Actions)
|
Tracker:
This bill
has the status Introduced
Here are the
steps for Status of Legislation:
1. Introduced
2. Passed Senate
3. Passed House
4. To President
5. Became Law
More on
This Bill
Subject —
Policy Area:
- Health
- View subjects
- Summary (1)
- Text (1)
- Actions (1)
- Titles (2)
- Amendments (0)
- Cosponsors (7)
- Committees (1)
- Related
Bills (2)
Summary: S.122
— 114th Congress (2015-2016)All
Bill Information (Except Text)
There is one
summary for S.122. Bill summaries are authored by CRS.
Shown
Here:
Introduced in Senate (01/08/2015)
Introduced in Senate (01/08/2015)
Safe and
Affordable Drugs from Canada Act of 2015
Amends the
Federal Food, Drug, and Cosmetic Act (FFDCA) to require the Department of
Health and Human Services (HHS) to promulgate regulations within 180 days
permitting individuals to import a prescription drug purchased from an approved
Canadian pharmacy that:
- is dispensed by a
pharmacist licensed in Canada;
- is purchased for
personal use in quantities not greater than a 90-day supply;
- is filled using a
valid prescription issued by a physician licensed to practice in the
United States; and
- has the same active
ingredient or ingredients, route of administration, dosage form, and
strength as a prescription drug approved under the FFDCA.
Sets forth
exceptions, including for controlled substances and biological products.
Establishes
a certification process for approving Canadian pharmacies. Requires HHS to
publish a list of approved Canadian pharmacies.
S.2023 - Prescription Drug Affordability Act of 2015 114th
Congress (2015-2016) | Get alerts
BILL
Sponsor:
|
Sen.
Sanders, Bernard [I-VT] (Introduced 09/10/2015)
|
Committees:
|
Senate - Finance
|
Latest Action:
|
09/10/2015 Read twice and referred to the
Committee on Finance. (All
Actions)
|
- Health
- View subjects
- Summary (1)
- Text (1)
- Actions (1)
- Titles (2)
- Amendments (0)
- Cosponsors (1)
- Committees (1)
- Related Bills (7)
- requires the Centers for Medicare & Medicaid to negotiate lower prices on behalf of beneficiaries for drugs covered under Medicare Part D;
- accelerates closure of the Medicare Part D coverage gap known as the "donut hole," under which beneficiaries who have reached a certain level of yearly drug costs become fully responsible for any additional drug costs up to a certain limit;
- requires drug manufacturers to issue rebates for prescription drugs dispensed to eligible low-income individuals under Medicare or Medicaid; and
- expands the application of certain prescription drug rebate requirements under Medicaid to include rebates for generic drugs.
The bill also requires drug manufacturers to produce and share annual reports containing specified information related to domestic and foreign sales.
Tracker:
This bill has the status Introduced
Here are the steps for Status of Legislation:
1. Introduced
2. Passed Senate
3. Passed House
4. To President
5. Became Law
More on This Bill
Subject — Policy Area:
Summary: S.2023 — 114th Congress (2015-2016)All
Bill Information (Except Text)
There is one summary for S.2023. Bill summaries are authored by CRS.
Shown Here:
Prescription Drug Affordability Act of 2015
This bill amends titles XVIII (Medicare) and XIX
(Medicaid) of the Social Security Act to modify provisions related to the
affordability of prescription drugs under the Medicare and Medicaid programs.
Specifically, the bill:
The bill also amends the Federal Food, Drug, and
Cosmetic Act to: (1) allow the importation by individuals of prescription
drugs from Canada and, potentially, other countries; and (2) establish
certain conditions on the award of market exclusivity with respect to
drugs. Specifically, a drug manufacturer's market exclusivity shall
be terminated if the manufacturer commits, or fails to report, a drug-related
violation such as misbranding, illegal marketing, or fraud.
In addition, the bill amends the Federal Trade
Commission Act to: (1) establish restrictions on certain anticompetitive patent
settlements known as "pay-for-delay" agreements, which effectively
block generic drug competition; and (2) allow the Federal Trade Commission to
initiate proceedings to enforce these restrictions against any parties to such
a settlement.
H.R.2623
- Personal Drug Importation Fairness Act of 2015114th Congress (2015-2016) | Get alerts
BILL
Sponsor:
|
Rep.
Ellison, Keith [D-MN-5] (Introduced 06/03/2015)
|
Committees:
|
House - Energy and Commerce
|
Latest
Action:
|
06/05/2015 Referred to the Subcommittee on
Health. (All
Actions)
|
Tracker:
This bill has the status Introduced
Here are the steps for Status of Legislation:
1.
Introduced
2. Passed House
3. Passed Senate
4. To President
5. Became Law
More
on This Bill
Subject
— Policy Area:
- Health
- View
subjects
- Summary
(1)
- Text
(1)
- Actions
(3)
- Titles
(2)
- Amendments
(0)
- Cosponsors
(7)
- Committees
(1)
- Related
Bills (0)
Summary: H.R.2623
— 114th Congress (2015-2016)All
Bill Information (Except Text)
There is one summary for H.R.2623. Bill summaries are authored by CRS.
Shown
Here:
Introduced in House (06/03/2015)
Introduced in House (06/03/2015)
Personal
Drug Importation Fairness Act of 2015
This bill allows a drug to be imported by a person
other than the drug's manufacturer if the drug: (1) has the same active
ingredients, route of administration, and strength as an approved drug; (2) may
be lawfully marketed in, and is imported or reimported from, a country included
on a list in this Act that the Food and Drug Administration determines has
standards for ensuring drug safety and effectiveness that are at least as
protective as U.S. standards; (3) is dispensed by a licensed pharmacist; (4) is
shipped directly to, or is imported by, the ultimate consumer; (5) is shipped
or imported in quantities that do not exceed a 90-day supply; (6) is
accompanied by a copy of a valid prescription; and (7) is not a controlled
substance.
No comments:
Post a Comment